文献速递慢性肾脏病肾小球疾病

欧洲肾癌流行病学

European epidemiology of kidney cancer.
PubMed 文献 · Nephrol Dial Transplant · 2026-09-24

基于GLOBOCAN 2024估计,2024年欧洲纳入国家新发肾癌116,582例、死亡42,516例;西欧绝对负担最大,但北欧和东欧年龄标化发病率中位数最高。男性发病约为女性两倍,多数病例和死亡发生在60岁以后。若2024年率不变,到2050年发病可能增加18.7%、死亡增加38.9%。

要点

  • 欧洲肾癌地理异质性显著,北欧和东欧年龄标化发病率中位数最高。
  • 男性发病约为女性两倍,多数病例和死亡发生在60岁以后。
  • 肾癌与慢性肾脏病共享代谢和行为危险因素,可能双向相关。

核心结论

  • 欧洲肾癌负担存在显著地理、性别和年龄异质性,发病率多数地区上升或稳定而死亡率多国下降或稳定。
  • 肾癌与慢性肾脏病共享主要代谢和行为危险因素,证据支持肾损伤与肾癌发生可能双向相关。
  • 肾病学在肾癌预防、肾功能保护和多学科癌症照护中具有重要作用。

研究设计与样本

  • 基于GLOBOCAN 2024估计的欧洲国家肾癌流行病学分析,整合地理、性别、年龄、时间及社会经济模式与危险因素证据。

主要发现

  • 2024年纳入国家估计新发肾癌116,582例、死亡42,516例。
  • 西欧绝对负担最大,但国家特异性年龄标化发病率中位数以北欧和东欧最高。
  • 男性肾癌发生频率约为女性两倍,多数病例和死亡发生在60岁以后。
  • 多数欧洲人群发病率上升或稳定,许多国家死亡率下降或稳定。
  • 若2024年率不变,到2050年发病病例可能增加18.7%、死亡增加38.9%。

关键数值与推荐

  • 2024年欧洲纳入国家估计新发肾癌116,582例、死亡42,516例。
  • 男性肾癌发生频率约为女性两倍,多数病例和死亡在60岁以后。
  • 若2024年率不变,2050年发病可能增加18.7%、死亡增加38.9%。

临床怎么用

  • 肾内科应关注肾癌与慢性肾脏病共享危险因素,参与肾癌预防和肾功能保护。
  • 肾癌照护需多学科协作,肾病学在其中具有重要作用。

局限性

  • 基于GLOBOCAN 2024估计,诊断强度、癌症登记和医疗可及性差异可能影响发病率地理分布解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Kidney cancer represents a substantial and heterogeneous health burden across Europe. Using contemporary GLOBOCAN 2024 estimates, we provide a granular assessment of kidney cancer epidemiology across European countries, integrating geographical, sex- and age-specific, temporal, and socioeconomic patterns with evidence on risk factors and the relationship between kidney cancer and kidney disease. In 2024, an estimated 116,582 new cases and 42,516 deaths occurred across the countries included. Although the absolute burden was greatest in Western Europe, median country-specific age-standardized incidence rates were highest in Northern and Eastern Europe, illustrating marked geographical heterogeneity. Kidney cancer occurred almost twice as frequently in males as in females, and most cases and deaths occurred after 60 years of age. Incidence has increased or remained stable in most European populations, while mortality has declined or stabilized in many countries. Demographic projections indicate that, if 2024 rates remain unchanged, incident cases may increase by 18.7% and deaths by 38.9% by 2050. Higher incidence in more affluent European countries does not consistently parallel the geographical distribution of established risk factors and may also reflect differences in diagnostic intensity, cancer registration, and healthcare access. Kidney cancer and chronic kidney disease share major metabolic and behavioural risk factors, while epidemiological and experimental evidence supports a potentially bidirectional relationship between kidney injury and renal carcinogenesis. These interactions highlight an important role for nephrology in kidney cancer prevention, preservation of kidney function, and multidisciplinary cancer care.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Koç NS. European epidemiology of kidney cancer. Nephrol Dial Transplant. 2026. PMID: 42784442. doi:10.1093/ndt/gfag216

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。